Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19

Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19

IntroductionTocilizumab, a humanized anti-interleukin-6 receptor (IL-6R) antibody, is recommended for the treatment of severe to critical coronavirus diseases 2019 (COVID-19). However, there were conflicting results on the efficacy of tocilizumab. Therefore, we hypothesized that the differences in t...

Full description

Bibliographic Details
Main Authors: Chan Mi Lee, Minji Kim, Chang Kyung Kang, Pyoeng Gyun Choe, Nam Joong Kim, Hyeeun Bang, Taeeun Cho, Hyun Mu Shin, Hang-Rae Kim, Wan Beom Park, Myoung-don Oh
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Immunology
Subjects:
immune response
cytokine
IL-6
T cell
critical COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1110874/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1110874/full

Similar Items